DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Interstitial granulomatous dermatitis associated with darifenacin.

Author(s): Mason HR, Swanson JK, Ho J, Patton TJ

Affiliation(s): Department of Dermatology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

Publication date & source: 2008-09, J Drugs Dermatol., 7(9):895-7.

Publication type: Case Reports

Interstitial granulomatous dermatitis is most commonly associated with rheumatoid arthritis (RA) but may be induced by medications as well. Darifenacin is a muscarinic antagonist which was FDA approved for the treatment of overactive bladder in December 2004. The authors describe a case of interstitial granulomatous dermatitis associated with darifenacin.

Page last updated: 2009-02-08

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017